Viemed Raises Revenue Guidance Despite Earnings Dip

Viemed Healthcare reported its fiscal 2026 Q2 earnings on Aug 03rd, 2026, marking a significant top-line expansion despite a slight contraction in bottom-line profitability. The company raised its full-year net revenue guidance, reflecting favorable operating trends, while simultaneously adjusting its Adjusted EBITDA forecast downward. This guidance revision indicates a strategic shift toward less capital-intensive revenue streams, aiming to enhance long-term financial flexibility and operational momentum for the remainder of the fiscal year.

Revenue

The total revenue of Viemed Healthcare increased by 23.9% to $78.10 million in 2026 Q2, up from $63.06 million in 2025 Q2. Revenue from rentals accounted for $52.82 million, driven primarily by ventilator rentals, both non-invasive and invasive, which contributed $36.41 million, while other home medical equipment rentals added $16.41 million. Revenue from sales and services reached $25.28 million, comprising $18.97 million from equipment and supply sales and $6.31 million in service revenues, bringing Total revenues to $78.10 million.

Earnings/Net Income

Viemed Healthcare's EPS declined 12.5% to $0.07 in 2026 Q2 from $0.08 in 2025 Q2. Meanwhile, the company's net income declined to $2.90 million in 2026 Q2, down 10.8% from $3.25 million reported in 2025 Q2. The Company has sustained profitability for 9 years over the corresponding fiscal quarter, reflecting stable business performance. The decline in earnings was partly offset by a non-recurring gain in the prior year period, suggesting underlying operational stability despite the reported decrease.

Price Action

The stock price of Viemed Healthcare has edged down 0.93% during the latest trading day, has dropped 3.55% during the most recent full trading week, and has edged down 0.43% month-to-date.

Post-Earnings Price Action Review

Viemed Healthcare's stock exhibited modest downward pressure in the immediate aftermath of the earnings release, reflecting a nuanced market reaction to the mixed financial results. Although the company achieved a record quarter in net revenues, the simultaneous decline in net income and adjusted EBITDA likely tempered investor enthusiasm. The stock edged down 0.93% on the latest trading day and dropped 3.55% over the most recent full trading week. Additionally, the share price has edged down 0.43% month-to-date, indicating a period of consolidation as investors digest the guidance revisions and the shift toward less capital-intensive revenue streams.

CEO Commentary

Casey Hoyt, Viemed’s CEO, highlighted another record quarter with $78.1 million in revenue and a historic ventilator patient census. He attributed strength to durable, diversified growth engines, including improved patient compliance, record PAP volume, and expansion in resupply and maternal health. Hoyt emphasized the company’s strong cash generation, solid balance sheet, and financial flexibility to invest in people, technology, and patient care. He expressed confidence in delivering consistent, increasingly predictable growth in the second half of 2026, driven by patient growth already entering the platform and deliberate strategic investments.

Guidance

Viemed raised its full-year 2026 net revenue guidance to $314–$320 million from $312–$320 million, citing favorable operating trends. Adjusted EBITDA guidance was revised downward to $64–$68 million from $65–$69 million. Net capital expenditures are expected to range from 8.5% to 10.0% of net revenue, down from 9.0% to 10.5%, reflecting increased contribution from less capital-intensive product and service revenue. The company expects this shift to support growing financial flexibility and sustained operational momentum throughout the remainder of the fiscal year.

Additional News

Viemed Healthcare announced significant share repurchase activity during the second quarter of 2026, reinforcing its commitment to capital allocation efficiency. The company repurchased and cancelled 530,802 common shares under its existing program at a total cost of $5.1 million, excluding taxes. This buyback was executed at an average price of $9.65 per share. These transactions occurred alongside the release of strong free cash flow figures, with the company generating $8.6 million in free cash flow for the quarter and $34.4 million over the trailing twelve months. The repurchases highlight management's confidence in the company's financial health and its strategy to return value to shareholders while maintaining the resources necessary for strategic investments in technology and personnel.